Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan/Feb;37(1):4-27.
doi: 10.1177/1091581817741840. Epub 2017 Dec 21.

Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular

Armaghan Emami  1 , Jeff Tepper  2 , Brian Short  3 , Tony L Yaksh  4 , Alison M Bendele  5 , Thulasi Ramani  6 , Alvaro F Cisternas  7 , Jay H Chang  1 , R Daniel Mellon  1
Affiliations

Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular

Armaghan Emami et al. Int J Toxicol. 2018 Jan/Feb.

Abstract

As the need for nasal, ocular, spinal, and articular therapeutic compounds increases, toxicology assessments of drugs administered via these routes play an important role in human safety. This symposium outlined the local and systemic evaluation to support safety during the development of these drugs in nonclinical models with some case studies. Discussions included selection of appropriate species for the intended route; conducting nonclinical studies that closely mimic the intended use with adequate duration; functional assessment, if deemed necessary; evaluation of local tissues with special histological staining procedure; and evaluations of safety margins based on local and systemic toxicity.

Keywords: analgesics; antispasticity; epidural; granuloma; intra-articular; intracameral; intranasal; intrathecal; intravitreal; local toxicity; safety evaluation; safety margins; spinal cord; toxicity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Ocular delivery routes (©Copyright 2016 DrugDel Consulting, LLC. Used with permission).
Figure 2
Figure 2
Adverse finding of epiretinal membrane in retinal of monkey eye injected intraviteally with implants. Note thick epiretinal membrane with nodular and linear arrays of cells on inner retinal layer. Underlying separation of retinal nuclear layers.
Figure 3
Figure 3
Nonadverse finding in cornea near limbus of dog injected with intracameral implants. Note small focal area of minimal endothelial hyperplasia in response to mechanical contact with implants.
Figure 4
Figure 4
Frontal section of normal rat knee shows shape of medial (med) and lateral (lat) sides with synovium (S), menisci (M) and cruciate (C) ligaments. Black arrows show extent of synovial space extending up the sides of the femur and arrow head shows the same on tibia. The red arrow indicates a cystic area of bone in which synovial fluid and any injected material might be present. (Toluidine blue, 16X).
Figure 5
Figure 5
Frontal section of rat knee injected with a toxic material shows synovium (S) that is thickened as a result of fibrosis and inflammation. Black arrows indicate tibial (lower) and femoral (upper) surfaces completely denuded of hyaline cartilage as a result of chondrocyte death. Red arrows indicate cartilage proliferation in the marginal zones, a common response to load bearing cartilage loss. Bone sclerosis is present on both medial (med) and lateral (lat) sides. (Toluidine blue, 16X).
Figure 6
Figure 6
Need for Safety Margins Based on both Local Injection Concentration and Local “Steady-state” Concentrations in a Virtual Space.
Figure 7
Figure 7
Hypothetical Example of Scaling Nonclinical Dosing to Mimic Human Dosing for “Virtual Space” injections.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Illum L. Nasal clearance in health and disease. J Aerosol Med. 2006 Spring;19(1):92–9. - PubMed
    1. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012 Jun;134(3):366–79. Reed (1993) - PubMed
    1. Fortuna A, Alves G, Serralheiro A, Sousa J, Falcão A. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm. 2014 Sep;88(1):8–27. - PubMed
    1. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014 Mar;21(2):75–86. - PubMed
    1. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288–311. Review. - PubMed

Publication types

MeSH terms

Substances

-